(NASDAQ: HBIO) Harvard Bioscience's forecast annual revenue growth rate of -7.26% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 59.56%.
Harvard Bioscience's revenue in 2025 is $94,135,000.On average, 1 Wall Street analysts forecast HBIO's revenue for 2025 to be $3,847,701,668, with the lowest HBIO revenue forecast at $3,847,701,668, and the highest HBIO revenue forecast at $3,847,701,668.
In 2026, HBIO is forecast to generate $4,209,112,363 in revenue, with the lowest revenue forecast at $4,209,112,363 and the highest revenue forecast at $4,209,112,363.